RLYB Key Statistics, Chart & Performance
The current stock price of RLYB is 0.7316 USD. In the past month the price increased by 12.69%. In the past year, price decreased by -19.95%.
RLYB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.33 | 406.30B | ||
| AMGN | AMGEN INC | 15.27 | 179.83B | ||
| GILD | GILEAD SCIENCES INC | 15.34 | 155.92B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.67 | 117.47B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.41 | 82.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.67 | 52.94B | ||
| INSM | INSMED INC | N/A | 37.84B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.53 | 25.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.5 | 22.16B | ||
| INCY | INCYTE CORP | 15.64 | 19.72B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About RLYB
Company Profile
Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. The company is headquartered in New Haven, Connecticut and currently employs 15 full-time employees. The company went IPO on 2021-07-29. The company has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
Company Info
RALLYBIO CORP
234 Church Street, Suite 1020
New Haven CONNECTICUT US
CEO: Martin W. Mackay
Employees: 20
Phone: 12038593820
RALLYBIO CORP / RLYB FAQ
What does RLYB do?
Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. The company is headquartered in New Haven, Connecticut and currently employs 15 full-time employees. The company went IPO on 2021-07-29. The company has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
What is the stock price of RALLYBIO CORP today?
The current stock price of RLYB is 0.7316 USD. The price decreased by -3.12% in the last trading session.
Does RLYB stock pay dividends?
RLYB does not pay a dividend.
What is the ChartMill technical and fundamental rating of RLYB stock?
RLYB has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does RALLYBIO CORP belong to?
RALLYBIO CORP (RLYB) operates in the Health Care sector and the Biotechnology industry.
Is RALLYBIO CORP (RLYB) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on RLYB.
Can you provide the short interest for RLYB stock?
The outstanding short interest for RALLYBIO CORP (RLYB) is 0.37% of its float.
RLYB Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to RLYB. When comparing the yearly performance of all stocks, RLYB turns out to be only a medium performer in the overall market: it outperformed 61.06% of all stocks.
RLYB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RLYB. RLYB has a great financial health rating, but its profitability evaluates not so good.
RLYB Financial Highlights
Over the last trailing twelve months RLYB reported a non-GAAP Earnings per Share(EPS) of -0.82. The EPS increased by 48.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.88% | ||
| ROE | -22.41% | ||
| Debt/Equity | 0 |
RLYB Forecast & Estimates
10 analysts have analysed RLYB and the average price target is 1.02 USD. This implies a price increase of 39.42% is expected in the next year compared to the current price of 0.7316.
For the next year, analysts expect an EPS growth of 71.04% and a revenue growth 8.72% for RLYB